Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 509079 | NSE Symbol : GUFICBIO | ISIN : INE742B01025 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
07-Feb-2025	14-Feb-2025	Quarterly Results	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve Unaudited Financial Results (Standalone And Consolidated) of the Company for the Quarter and Nine Months ended December 31 2024 Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024 is attached herewith. (As Per Bse Announcement Dated on 14.02.2025)
27-Dec-2024	27-Dec-2024	Change in Directors	Outcome of the Board of Directors Meeting held on Friday, December 27, 2024 is attached herewith
08-Nov-2024	14-Nov-2024	Quarterly Results	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve Unaudited Financial Results (Standalone And Consolidated) of the Company for the quarter and half year ended September 30 2024 Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024 is attached herewith. (As per BSE Announcement dated on 14/11/2024)
25-Sep-2024	25-Sep-2024	Change in Directors	Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. September 25, 2024, inter-alia, considered the matters attached herewith
08-Aug-2024	14-Aug-2024	Quarterly Results	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Unaudited Financial Results (Standalone And Consolidated) of the Company for the Quarter ended June 30 2024 Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. August 14, 2024, has, inter-alia, considered and approved the matters attached herewith. (As per BSE Announcement dated on 14/08/2024)
27-Jun-2024	27-Jun-2024	Change in Directors	Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. June 27, 2024, inter-alia, considered and approved the matters which is attached herewith. The meeting of the Board of Directors commenced at 04:00 p.m. and concluded at 05:00 p.m.
22-May-2024	29-May-2024	Final Dividend	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve 1. Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Financial Year ended March 31 2024. 2. Recommend a final dividend if any on the equity shares of the Company for the Financial Year 2023-24 subject to approval of shareholders at their ensuing Annual General Meeting. Outcome of Board Meeting held on 29.05.2024 is attached herewith. Outcome of Board Meeting held on 29.05.2024 is attached herewith. (As Per BSE Announcement dated on 29.05.2024)
25-Apr-2024	25-Apr-2024	Change in Directors	We wish to inform you that consequent upon the demise of Mr. Shrirang Vishwanath Vaidya, former Independent Director of the Company, and pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), the Board of Directors of the Company at its meeting held today, i.e. on Thursday, April 25, 2024, inter-alia, considered and approved reconstitution of various committees of the Board, as attached, with effect from April 25, 2024. The meeting of the Board of Directors commenced at 03:30 p.m. and concluded at 05:30 p.m.
07-Feb-2024	14-Feb-2024	Quarterly Results	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31 2023. Further in continuation to our disclosure on the Closure of Trading Window dated December 28 2023 and pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 the trading window in respect of dealing in the Equity Shares of the Company for all the Designated Persons of the Company along with their immediate relatives shall continue to remain closed until 48 hours post declaration of the said financial results. Pursuant to Regulation 30 (read with Part A of Schedule III) and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. on Wednesday, February 14, 2024, inter-alia, considered the following matters: 1. Approval of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2023 2. Increase in Subscribed Share Capital of Gufic UK Limited, Wholly Owned Subsidiary of the Company 3. Formation/ Incorporation of Company under Section 8 of the Companies Act, 2013 in India for undertaking Corporate Social Responsibility initiatives. The meeting of the Board of Directors commenced at 03:30 p.m. and concluded at 5:30 p.m. Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023 along with Limited Review Report thereon, is enclosed herewith. Statement of deviation(s) or variation(s) in the use of proceeds of Preferential Issue of Equity Shares for the quarter ended December 31, 2023 is attached herewith (As per BSE Announcement Dated on 14/02/2024)
02-Nov-2023	09-Nov-2023	Quarterly Results	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30 2023. Further in continuation to our disclosure on the Closure of Trading Window dated September 28 2023 and pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 the trading window in respect of dealing in the Equity Shares of the Company for all the Designated Persons of the Company along with their immediate relatives shall continue to remain closed until 48 hours post declaration of the said financial results. Please find attached herewith Unaudited Standalone and Consolidated Financial Results for the Quarter and half year ended September 30, 2023 Pursuant to Regulation 30 (read with Part A of Schedule III) and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. on Thursday, November 09, 2023, inter-alia, considered the following matters: 1. Approval of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2023; 2. Re-appointment of M/s. Manish Ghia & Associates, Practicing Company Secretaries, Mumbai, as the Secretarial Auditor of the Company; The meeting of the Board of Directors commenced at 03:00 p.m. and concluded at 5:30 p.m. (As Per BSE Announcement dated on 09.11.2023)
11-Oct-2023	11-Oct-2023	Preferential Issue	Outcome of the Board of Directors Meeting held on Wednesday, October 11, 2023 is attached herewith Outcome of Board of Directors meeting held on Wednesday, October 11, 2023 is attached herewith.
27-Sep-2023	27-Sep-2023	Subsidiary Company	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') (including any statutory modification(s), amendment(s) and re-enactment(s) thereof), this is to inform that Board of Directors of the Company at its Meeting held today i.e. Wednesday, September 27, 2023, inter alia, considered and approved the Incorporation of Wholly Owned Subsidiary in Dubai, UAE. The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are attached herewith as 'Annexure A'. The meeting of the Board of Directors commenced at 03:00 p.m. and concluded at 04:15 p.m. Outcome of Board of Directors Meeting held on Wednesday, September 27, 2023 is attached herewith.
29-Aug-2023	01-Sep-2023	Preferential Issue	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2023 inter alia to consider and approve the proposal for raising of funds by issuance of equity shares by way of a preferential allotment or through any other permissible mode as may be considered appropriate in one or more tranches subject to approval of the shareholders in the ensuing Annual General Meeting and such other regulatory / statutory authorities as may be required. This is to inform that the Board of Directors of the Company at its Meeting held today i.e. Friday, September 01, 2023, considered and approved the following, amongst others: 1. Issuance of 33,33,000 equity shares of face value of Re. 1/- each ('Equity Shares') to M/s. Motilal Oswal Financial Services Limited, on a preferential basis ('Preferential Issue') at a price of Rs. 300/- per Equity Share aggregating to Rs. 99,99,00,000/- (Rupees Ninety-Nine Crores and Ninety Nine Lakhs Only), subject to the approval of the Members of the Company and such other regulatory/statutory authorities. The relevant date for determining the issue price for the said Preferential Issue is August 30, 2023. 2. Convening of 39th AGM of the shareholders of the Company on September 29, 2023 through Video Conferencing or Other Audio Visual Means seeking approval of the shareholders, interalia, for the aforementioned Preferential Issue. (As Per BSE Announcement Dated on 01/09/2023)
04-Aug-2023	11-Aug-2023	Quarterly Results	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve 1)Unaudited Financial Results of the Company for the Quarter ended 30.06.2023 along with the Limited Review Report issued by the Statutory Auditors thereon. 2)Gufic Biosciences Limited Employees Stock Options Plan 2023 subject to approval of shareholders of the Company at the ensuing Annual General Meeting and such other approvals as may be required. Further in continuation to our disclosure on the Closure of Trading Window dated 29.06.2023 the trading window in respect of dealing in the Equity Shares of the Company for all the Designated Persons of the Company along with their immediate relatives shall continue to remain close until 48 hours post declaration of the said financial results. In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at its meeting held today i.e., Friday, August 11, 2023 inter alia, considered and approved Unaudited Financial results of the Company for the quarter ended June 30, 2023 along with Limited Review Report issued thereon. (As Per BSE Announcement Dated on 11.08.2023) Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at its Meeting held today i.e. Friday, August 11, 2023, inter alia, considered and approved the following: 1. Unaudited Financial Results of the Company along with the Limited Review Report for the quarter ended June 30, 2023, which has been duly reviewed and recommended by the Audit Committee. 2. Gufic Biosciences Limited Employee Stock Option Plan 2023 , in compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. 3. Investment by way of subscription to the securities of a private limited company to be incorporated in India as a subsidiary of the Company. 4. Amendments to the 'Policy for Determination of Materiality of Events & Information' . The meeting of the Board of Directors commenced at 2:30 p.m. and concluded at 5:10 p.m. With reference to our earlier submission regarding Outcome of Board of Directors Meeting on August 11, 2023 vide ref no. 153/LG/SE/AUG/2023/GBSL, we would like to inform that the Company has noted a typographical error in the 'Annexure C' of the said submission. This annexure pertains to details of investment by way of subscription to the securities of a private limited company to be incorporated in India as a subsidiary of the Company as required under Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023. In this annexure, the no. of equity shares to be acquired by way of subscription to the securities of a Private Limited Company to be incorporated in India as a subsidiary of the Company was inadvertently mentioned as 80,000 equity shares (80% of equity share capital) instead of 88,000 equity shares (88% of equity share capital). Accordingly details of Point 7,8,9 in 'Annexure C' shall be read as attached. (As Per BSE Announcement Dated on 19.08.2023)
22-May-2023	29-May-2023	Accounts	GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2023 inter alia to consider and approve 1. The Audited Financial Results of the Company for the Quarter and Financial Year ended March 31 2023. 2. Recommend dividend if any for the Financial Year 2022-23 subject to approval of shareholders at their ensuing Annual General Meeting. Further in continuation to our disclosure on Closure of Trading Window dated March 30 2023 and pursuant to the Companys Code of Conduct for Prevention of Insider Trading framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 the trading window in respect of dealing in the Equity Shares of the Company for all the Designated Persons of the Company along with their immediate relatives shall continue to remain closed until 48 hours post declaration of the said financial results. Final Dividend & Audited Results (As per BSE Bulletin dated on 23/05/2023) In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) and re-enactment(s) thereof), this is to inform that the Board of Directors of the Company at its Meeting held today i.e. Monday, May 29, 2023, inter alia, recommended Dividend @ 10% i.e. Re. 0.10 per equity share (Face Value of Re. 1/- each) for the Financial Year ended March 31, 2023, subject to the approval of the Shareholders at the ensuing Annual General Meeting In compliance with the Regulation 30 and 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the company at its meeting held today i.e., Monday, May 29, 2023 inter alia considered and approved the Audited Financial Results of the company for the quarter and year ended March 31, 2023 along with the Auditors Report. In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') (including any statutory modification(s), amendment(s) and re-enactment(s) thereof), this is to inform that the Board of Directors of the Company at its Meeting held today i.e. Monday, May 29, 2023, inter alia, considered and approved the following: 1. The Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023 along with the Auditors Report. 2. Recommended Dividend @ 10% i.e. Re. 0.10 per equity share (Face Value of Re. 1/- each) for the Financial Year ended March 31, 2023, subject to the approval of the Shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated on 29/05/2023)

1 2 3

LOGIN HERE

Gufic BioSciences Ltd

Board Meeting